Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? (Q44683661)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? |
scientific article |
Statements
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? (English)
Abass Alavi
Edward A Stadtmauer
Robert M Sharkey
Arnold Brenner
Jack Burton
George Hajjar
Stephen P Toder
Alexander Matthies
Donald E Tsai
Stephen J Schuster
Myron S Czuczman
Dominick Lamonica
Françoise Kraeber-Bodere
Beatrice Mahe
Jean-François Chatal
André Rogatko
George Mardirrosian
David M Goldenberg
1 December 2003